Business Wire

Toshiba’s Breakthrough Algorithm Harnesses Edge of Chaos to Dramatically Boost Performance of its Quantum‑Inspired Computer

7.4.2026 09:00:00 CEST | Business Wire | Press release

Share

~Approximately 100 times faster, will accelerate solutions for drug discovery, finance, and other complex problems~

Toshiba Corporation has developed a breakthrough algorithm that dramatically boosts the performance of the Simulated Bifurcation Machine (SBM), its proprietary quantum‑inspired combinatorial optimization computer. The new algorithm significantly improves the probability of obtaining an optimal solution or a known best solution within a limited number of trials—referred to as the success probability, a key benchmark for evaluating combinatorial optimization technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407918434/en/

Figure 1: Results demonstrating that the newly developed third‑generation SB algorithm can find the known best solution with nearly 100% probability at the edge of chaos for a fully connected 2,000‑spin Ising problem.

The SBM is designed to solve large‑scale combinatorial optimization problems in a wide range of fields, including new drug discovery, delivery route optimization, and investment portfolio design. While previous algorithms could find optimal or known best solutions with a sufficiently large number of trials, large‑scale problems often trapped the search process in local optima, significantly lowering success probability under practical constraints that limit the number of trials.

Toshiba has overcome this challenge by developing a third‑generation simulated bifurcation (SB) algorithm. This ground-breaking advance builds on the original SB algorithm, announced in April 2019*1, and the second‑generation SB algorithm, released in February 2021*2, which delivered major boosts to computational speed and accuracy.

The new algorithm expands the bifurcation parameter that triggers the bifurcation phenomena*3—a defining feature of the SB algorithm—from a single global parameter to individual parameters assigned to each position variable*4. These bifurcation parameters are independently controlled according to the values of the corresponding position variables, enabling a more adaptive and effective solution search.

With the introduction of this advanced control mechanism, the algorithm exhibits either regular or chaotic behavior*5, depending on conditions. Crucially, Toshiba discovered that by effectively harnessing chaos at the edge of chaos—the boundary between regular dynamics and chaotic motion—the algorithm can escape local optima far more efficiently. As a result, the success probability of reaching the global optimum increases dramatically, approaching 100%.

The SBM based on the new algorithm is therefore much faster. It delivers a time to solution (TTS) required to obtain an optimal or known best solution that is approximately 100 times faster than the SBM based on the second‑generation algorithm. These advances are expected to accelerate the practical applications of combinatorial optimization across a broad range of challenges.

The research results were published in the April 6, 2026 issue of Physical Review Applied, a peer‑reviewed journal of the American Physical Society*6.

Note:
*1 https://advances.sciencemag.org/content/5/4/eaav2372
*2 https://advances.sciencemag.org/content/7/6/eabe7953
*3 In nonlinear dynamical systems, a phenomenon in which changes in system parameters (bifurcation parameters) cause the number of stable points to change from one to multiple.
*4 In the SB algorithm, the equations of motion of a classical dynamical system consisting of many oscillators are solved. A position variable represents the position of each oscillator, and these position variables correspond to the decision variables (discrete variables) of the combinatorial optimization problem.
*5 In nonlinear dynamical systems, a phenomenon in which even slight differences in initial conditions cause the subsequent trajectories of motion to diverge significantly, resulting in disordered (chaotic) behavior. This sensitivity of chaos to initial conditions is known as the butterfly effect, and the upper panel of Figure 1 provides a quantitative evaluation of this effect.
*6 https://doi.org/10.1103/2qd9-x6v8

About Toshiba
For over 150 years, guided by its corporate philosophy, “Committed to People, Committed to the Future.,” Toshiba Group has contributed to society through its business activities. Today, the Group continues to enhance its management structure, streamline operations, and invest in forward‑looking businesses in the energy, digital infrastructure, and electronic devices domains.
Annual sales in fiscal year 2025 were 3.5 trillion yen, with 95,000 employees worldwide. Find out more on our website or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260407918434/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye